Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Preclinical data supports further development of ALD1613
May 2016
SHARING OPTIONS:

BOTHELL, Wash.—The Endocrine Society's 98th Annual Meeting saw Alder BioPharmaceuticals Inc. present preclinical data for ALD1613, an anti-adrenocorticotropic hormone (ACTH) antibody for the treatment of congenital adrenal hyperplasia and Cushing's disease. ALD1613 was found to inhibit ACTH-induced cortisol secretion in a mouse adrenal cell line in vitro, and administration in rats with artificially elevated ACTH and corticosterone levels let to a rapid, durable reduction of plasma corticosterone levels. In non-human primates, ALD1613 was found to demonstrate stable, durable reductions in plasma cortisol levels by more than 50 percent.
 
“Existing therapeutic options for patients with congenital adrenal hyperplasia and Cushing's disease comprise treatments that provide limited disease control and involve significant side effects. We believe these limitations indicate a clear need for new therapies such as ALD1613, which targets ACTH to diminish the overproduction of cortisol,” said Dr. Randall C. Schatzman, Alder's president and CEO, adding that the company plans to submit an IND filing for ALD1613 in the second half of this year.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.